We research, we develop, we bring true innovations to the marketplace. Is that also your goal? Do you also want to sustainably improve the lives of our patients?
Are you an innovative researcher, an unconventional thinker, a strategist, a visionary, a creative thinker, a pragmatist, or a go-getter? In short, are you a person who will rise to the challenge and make a difference?
Then we look forward to telling you more about Grünenthal—about us, what makes us tick, and how we can reach our goals together - every day, worldwide.
Aachen, Germany, February 01, 2018 – Grünenthal announced today that Adhesys Medical Inc., a wholly-owned subsidiary of Grünenthal, has been granted Expedited Access Pathway (EAP) designation by the U.S. Food and Drug Administration (FDA) for VIVO. VIVO is a surgical sealant proposed for being an adjunct to standard closure techniques in gastrointestinal procedures to reduce intestinal leakage. VIVO is a candidate from Grünenthal’s innovative development-pipeline of surgical sealants. Flix®, the first product from this portfolio, already obtained CE-Certification in Europe.
Aachen, January 23, 2018 – Grünenthal announced today that it has entered into a distribution agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for distributing, promoting and selling MSD’s Women’s Health products in Brazil, Central America, Colombia, Mexico and Peru. The portfolio comprises several Women’s Health products, including Zoely®, Nuvaring®, Cerazette® and Livial®. MSD will continue to commercialize Nexplanon®/Implanon NXT® throughout that region.